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Objectives This study sought to examine the effects of vasopressin V2 receptor antagonism with tolvaptan on the changes
in left ventricular (LV) volumes over time.
Background Vasopressin levels may be increased in patients with heart failure (HF) and may be a factor driving the progres-
sion of HF.
Methods This was a multicenter, randomized, double-blind, placebo-controlled trial conducted to evaluate the effect of
long-term administration of the vasopressin V2-receptor antagonist tolvaptan (30 mg/day) on reducing left ven-
tricular end-diastolic volume (LVEDV) compared with placebo in patients with HF and reduced systolic function,
using quantitative radionuclide ventriculography at baseline, repeated after 1 year of therapy, and repeated
again approximately 1 week after withdrawal of study drug.
Results A total of 120 patients were randomized to tolvaptan and 120 were randomized to placebo. In the placebo
group, there was no change in LVEDV over the course of follow-up (change of 0.0  10.0 ml/m2). After 1 year of
tolvaptan, there was a small reduction in LV volume (decrease of 1.8  10.7 ml/m2); the between-group differ-
ence was not significant (p  0.21). During the course of the trial, there were 6 deaths (5%) and 21 HF hospital-
izations (18%) in the tolvaptan group, compared with 11 deaths (9%) and 34 HF hospitalizations (28%) in the
placebo group. In a time-to-event analysis, there was a significant favorable effect of tolvaptan on the composite
of mortality or heart failure hospitalization (p  0.03 by log-rank test).
Conclusions In a well-treated population of stable HF patients, there was no significant effect of tolvaptan therapy on LV
volumes observed during 1 year of therapy. Nonprespecified natural history data favored therapy with
tolvaptan, with a reduction in the combined end point of mortality and heart failure hospitalization ob-
served. (Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of
Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients; http://clinicaltrials.gov/ct/
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Arginine vasopressin has antidiuretic properties
that contribute to fluid retention and hypona-
tremia in patients with heart failure (HF) (1). It
exerts its antidiuretic effect in the kidney col-
lecting duct by binding to V2 receptors, causing
solute-free water reabsorption and formation of
concentrated urine (2). Studies using vasopressin receptor
ntagonists have demonstrated a significant increase in
See page 2160
olute-free water diuresis in patients with HF (3). Thus, V2
eceptor antagonists may provide beneficial therapy in
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HF without causing electrolyte
imbalances that are observed
with the use of other diuretics.
Tolvaptan is an oral, nonpeptide,
arginine vasopressin V2 receptor
antagonist that, in studies to date
in HF patient populations, has
been associated with reduction in
body weight consistent with im-
proved volume homeostasis (4),
as well as normalization in serum
sodium in hyponatremic HF pa-
tients (5).
In patients with HF and re-
duced ejection fraction (EF),
there is now substantial evidence
to support the concept that the
left ventricle (LV) progressively
ilates and that this process is associated with adverse
onsequences for natural history. It has been reported that
his process, which results from LV remodeling and con-
inues long after the time of the initial myocardial injury, is
revented or reversed by long-term angiotensin-converting
nzyme (ACE) inhibitor administration as well as beta-
lockade in human HF (6–9), suggesting that prevention or
eversal of remodeling is associated with more favorable
atural history outcomes. These data form a rationale for
xamining the effects of a new therapy such as tolvaptan on
hanges in LV volumes over time.
ethods
tudy design. This was a multicenter, randomized,
ouble-blind, placebo-controlled study of the nonpeptide
asopressin V2 receptor antagonist tolvaptan in patients
ith HF and reduced LV systolic function. The primary
bjective was to evaluate the effect of long-term adminis-
ration of tolvaptan at a dose of 30 mg/day on left ventric-
lar end-diastolic volume (LVEDV) compared with placebo
n such patients. Patients underwent quantitative radionu-
lide ventriculography (RVG) at baseline, which was re-
eated after 1 year of therapy with tolvaptan or placebo, and
epeated again approximately 1 week after withdrawal of the
tudy drug. The withdrawal study allows examination of the
ffect of long-term treatment on LV volumes in the absence
f any dose-by-dose loading effects and has been used in
revious studies (7,10).
atient population. Patients with New York Heart Asso-
iation functional class II to III HF who were at least 18
ears of age and who had an ejection fraction 30% within
year were eligible for screening. Patients were to be on
tandard background therapy for HF, including beta-
locker therapy, ACE inhibitor, or angiotensin receptor
locker therapy if they were ACE inhibitor intolerant. They
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
BUN  blood urea nitrogen
EF  ejection fraction
HF  heart failure
LAO  left anterior oblique
LV  left ventricular
LVEDV  left ventricular
end-diastolic volume
LVEF  left ventricular
ejection fraction
LVESVi  left ventricular
end-systolic volume index
RVG  radionuclide
ventriculographyust have been receiving such therapy for 3 months before Anrollment and on a stable dose for 2 weeks before enroll-
ent. Exclusion criteria comprised but were not limited to
he following: women of childbearing potential not using
cceptable double-barrier contraceptive methods, cardiac
urgery within 90 days, biventricular pacing device im-
lanted within 2 months, percutaneous coronary interven-
ions or implantable cardioverter-defibrillator implant
ithin 2 months of potential study enrollment, history of a
yocardial infarction (documented by electrocardiogram or
nzymes) within 3 months, systolic arterial blood pressure
90 mm Hg at screening, and serum creatinine3.0 mg/dl
r blood urea nitrogen (BUN) 60 mg/dl. Institutional
eview boards at all trial sites approved the study protocol,
nd all patients signed informed consent to participate.
tudy drug administration. The study drug was to be
dministered orally at approximately 9:00 AM. Patients were
andomized to receive either tolvaptan 30 mg or matching
lacebo in a double-blinded fashion. Patients remained on
oncomitant medications during the study; however, all
ardiac medications, with the exception of short-acting
itrates if needed, were to be withheld for at least 6 h before
VG acquisitions. The choice of the 30 mg dose of
olvaptan was based on previous studies and is the dose
eing used in a long-term mortality trial (11).
VG. The RVG methodology was developed and directed
y a central core laboratory as reported in previous studies
7,10,12), with detailed instructions and quality control
rocedures reviewed at an Investigator Meeting, and with
omments on image quality fed back to sites after each RVG
as received in the core laboratory. Equilibrium-gated
VGs were performed after modified in vivo red blood cell
abeling with Tc-99m. A gamma camera was positioned in
he modified left anterior oblique (LAO) view using a
igh-resolution parallel-hole collimator, with the degree of
bliquity chosen to maximize interventricular and right
trioventricular separation. An approximate 10° caudal tilt
ould be applied to avoid atrial overlap and further enhance
hamber separation. The gated LAO scans were acquired
or 8 min or for a minimum of 5 million counts in a 16-bit
aseline Characteristics of the Population Sample
Table 1 Baseline Characteristics of the Population Sample
Tolvaptan
(n  120)
Placebo
(n  120)
Gender, % (M/F) 82/18 81/19
Age, yrs (SD) 65 (12) 63 (12)
Race (% Caucasian) 87 88
Weight, kg (SD) 85 (18) 92 (21)
Hypertension (%) 58 67
Diabetes mellitus (%) 41 33
HF ischemic etiology (%) 62 71
Background medications
ACE inhibitor/ARB (%) 89 90
Beta-blocker (%) 89 89
Aldosterone antagonist (%) 36 39
Diuretic (%) 90 91CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; HF  heart failure.
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June 5, 2007:2151–9 Effect of Vasopressin Antagonism on Remodelingord mode, 64  64 matrix, with a 15% window centered
t the Tc-99m photopeak. Data acquisition was gated to the
atient’s electrocardiogram, with each cardiac cycle divided
nto 32 frames.
A 5-ml heparinized blood sample was drawn midway
hrough the acquisition, placed in a lavender top tube or
ater pipetted onto a Petri dish, for ventricular volume
alculations. Two methods could be used for collecting
recise blood samples (7,10,12). In method I, the sample
as weighed to calculate the exact volume before counting
t on the camera. In method II, an exact volume of blood
as pipetted onto a Petri dish and counted on the camera.
fter completion of the gated scan in the LAO projection,
wo 1-min static scans were obtained, for the purpose of
ttenuation correction. This depth acquisition was acquired
n a 16-bit word mode, 64  64 matrix, single file
ontaining two frames. The first frame was in the same
xact LAO projection as the rest LAO scan, and the second
rame was in the anterior position.
Activity in the blood sample was counted during a 2-min,
6-bit word mode, 64  64 matrix acquisition, after the
ated and depth images were completed. The single-frame
tatic image was acquired using the same gamma camera
nd collimator as used for the gated LAO and depth
cquisitions. The precise time of the patient and blood
ample acquisitions were recorded to permit accurate decay
orrection. Volumetric measurements and calculation of
jection fraction were performed in a central core laboratory
y an experienced technologist and nuclear cardiologist who
ere blinded to the treatment group and clinical data. The
alculation of volumes was based on previously published
ethods (7,10,12,13).
atient Disposition
Table 2 Patient Disposition
Tolvaptan
(n  120) n (%)
Placebo
(n  120) n (%)
Treated 120 100 120 100
Discontinued 29 24.2 31 25.8
Lost to follow-up 1 0.8 0 0
Adverse events 14 11.7 15 12.5
Subject met withdrawal criteria 1 0.8 2 1.7
Investigator withdrew subject 1 0.8 0 0
Subject withdrew consent 12 10.0 13 10.8
Protocol deviation 0 0 1 0.8
Completed 91 75.8 89 74.2
aseline and Changes Across the Study in Left Ventricular Volume
Table 3 Baseline and Changes Across the Study in Left Ventric
Baseline (Mean  SD)  Week 54 (M
Tolvaptan Placebo Tolvaptan Pla
LVEDVI (ml/m2) 179.9 43.5 176.4 41.6 1.78 10.7 0.04
LVESVI (ml/m2) 139.6 39.6 136.1 38.1 3.28 12.6 0.41
LVEF (%) 23.0 5.0 23.7 5.2 1.32 4.1 0.52Comparison versus baseline; †comparisons versus Week 54. Changes are compared with baseline.
LVEDVI  left ventricular end-diastolic volume indexed to body surface area; LVEF  left ventricular ejssessment of symptom changes. The overall treatment
ffect assessment scale was used to determine whether there
ere any changes in the way each subject had been feeling
ince study treatment began. Subjects were asked the fol-
owing questions: “Since treatment started, has there been
ny change in your activity limitations, symptoms, and/or
motions related to your heart condition?” Subjects could
espond with 1 of 3 answers: better, about the same, or
orse. If subjects answered “better” or “worse,” they were
sked to rate their answer on a 7-item scale (hardly
etter/worse at all, a little better/worse, somewhat better/
orse, moderately better/worse, a good deal better/worse, a
reat deal better/worse, a very great deal better/worse).
ubjects also completed the Minnesota Living With Heart
ailure Questionnaire (14) on day 1, week 28, and week 54.
ubjects were asked to rate 21 items with respect to how
ach one prevented them from living as they wanted during
he last month (in relation to their HF). Each item was
ated on a scale from 0 (no effect), 1 (very little), to 5 (very
uch).
tatistical analysis and sample size calculations. The
rimary outcome variable was prospectively defined as the
hange from baseline in LV end diastolic volume index
adjusted for body surface, i.e., LVEDV per m2, LVEDVI)
t the week 54 visit. The change from baseline was analyzed
y fitting an analysis of covariance model with terms of
reatment, beta-blocker use (as yes or no), and baseline
olume as covariate. The treatment comparison of tolvaptan
ersus placebo was estimated by difference of least squares
eans derived from a type III analysis (SAS Institute, Cary,
orth Carolina). Statistical significance of this treatment
omparison was assessed at a 0.05 significance level. Only
atients having both baseline and a post baseline measure-
ent on LVEDVI were included in this analysis. As a
econdary analysis, a comparison of the change from base-
ine in LVEDVI at the postdrug withdrawal (week 55 visit)
as conducted.
For the subject-assessed symptom scales (global status
nd respiratory status), and the Minnesota Living With
eart Failure Questionnaire, comparisons between tolvap-
an and placebo were performed by visit using an analysis of
ovariance model with terms of treatment, beta-blocker use
yes or no), and baseline measurement. Comparison in
verall treatment effect assessment scale was made using the
Function
Volumes and Function
SD)  Week 55 (Mean  SD)
p Value* Tolvaptan Placebo p Value* p Value†
.0 0.21 0.42 11 0.72 9.9 0.76 0.09
.1 0.09 1.67 12.6 1.06 11.7 0.61 0.08
0.16 1.44 4.2 0.88 3.9 0.35 0.72s and
ular
ean 
cebo
 10
 12
 3.5ection fraction; LVESVI  left ventricular end-systolic volume indexed to body surface area.
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tratified by beta-blocker use.
Sample size calculation was based on the means and
tandard deviations of the change from baseline in LVEDV
ndex after 1 year of treatment noted in a previous study
sing similar methodology (10). On the basis of an approx-
mate pooled estimate of a standard deviation of 9.3 for the
hange in LVEDV index, the projected sample size for this
tudy was 68 patients per treatment group to detect a
ifference of 4.5 ml/m2 in mean change from baseline
etween tolvaptan and placebo (by 2-sample t-test) at 0.05
ignificant level and 80% power. Assuming a 20% dropout
ate, the total number of patients to be recruited in the study
as 170. For purposes of acquiring more extensive long-
erm safety data on the active therapy, study sample size was
ncreased to 240 patients.
esults
tudy population and disposition. A total of 240 patients
ere enrolled and randomized, 120 to the active drug group
nd 120 to placebo. The baseline characteristics of the
opulation are summarized in Table 1. There were no
ifferences in baseline parameters between the groups. Of
ote, this was a well-treated population with regard
o evidence-based HF therapies: 94% of patients were
reated with an ACE inhibitor or an angiotensin receptor
locker, and 89% of the population was treated with a
eta-blocker.
Of the 120 patients in each group having baseline studies,
1 patients in the tolvaptan group and 89 patients in the
lacebo group underwent week 54 RVGs for evaluation of
reatment effect. Reasons for discontinuation are listed in
able 2.
ffect of tolvaptan on ventricular volumes and function.
eft ventricular volumes and EF were similar between the
roups at baseline, as shown in Table 3. The population had
dvanced LV dysfunction, with baseline LVEF approxi-
ately 23%. Changes in LV volumes and function over the
-year course of the trial also are shown in Table 3. In the
lacebo group, there was no change in LVEDV index over
he year of follow-up (change of 0.0  10.0 ml/m2), i.e., no
vidence of progressive LV remodeling in this group of
atients on standard background therapy. After 1 year of
olvaptan therapy, there was a small reduction in LVEDV
ndex (decrease of 1.8  10.7 ml/m2); the between-group
ifference was not significant (p  0.21). There was also no
ifference in the change of volumes from baseline at the
eek 55 study.
Secondary end points included the evaluation of changes
n left ventricular end-systolic volume index (LVESVi) and
VEF. For LVESVi, in the placebo group, there was a
mall reduction over the year of follow-up (a decrease of
.4  12.0 ml/m2), whereas LVESVi decreased by 3.3 
2.6 ml/m2 on tolvaptan; the between-group difference wasnot significant (p  0.09). There was no difference in theT
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jection fraction changes also were small and directionally
imilar (Table 3).
An analytic issue inherent in studies of changes in
entricular volumes and function over the course of a trial is
he handling of “noncompleters,” i.e., patients who did not
ave the late follow-up imaging study. The data in Table 3
epresent patients completing the late follow-up studies. To
nvestigate the potential impact of patients who did not
omplete the study, we re-analyzed the data using 3 impu-
ation techniques, as in previous studies (7). Patients who
id not complete the study were assigned a change in
olume or function that was representative of either 1) no
hange from baseline, 2) the median change in their
andomization group, or 3) the worst change in their
andomization group. With any of these imputations, the
eneral direction and magnitude of the data were similar to
he primary data reported in Table 3.
ffects on vital signs and laboratory parameters. Only
inor changes in blood pressure and heart rate were
bserved over the course of the trial (Table 4); there were no
ignificant differences in the tolvaptan versus placebo
roups. There were no significant between-group differ-
nces in serum sodium or potassium across the course of the
rial. There were also no differences in renal function
arameters (BUN and serum creatinine) across the year of
herapy.
ffects on measures of symptom status. No statistically
ignificant differences were observed between the tolvaptan
roup and the placebo group for the change from baseline in
innesota Living With Heart Failure Questionnaire score
r for the Visual Analog Scale assessment of global status or
espiratory status (Table 5). Patients’ assessments of their
lobal status (better, worse, unchanged) are shown in Table 6.
verall, more subjects in the tolvaptan group reported a
core of “better” in the subject-assessed overall treatment
ffect at each visit than did subjects in the placebo group;
owever, no statistically significant differences were ob-
erved between treatment groups.
ffects on natural history outcomes. Outcomes of mor-
ality and HF hospitalizations were reported by investigators
ho were blinded to randomization treatment assignment,
.e., the outcomes were not adjudicated by a central events
djudication committee. During the course of the trial, there
ere 6 deaths (5%) and 21 hospitalizations of patients with
atient Global Assessment Changes by the MLHQ and VAS Scoring
Table 5 Patient Global Assessment Changes by the MLHQ and
Baseline (Mean)
Tolvaptan Placebo Tolvaptan
MLHQ total score 40.5 (23.1) 46.1 (23.3) 4.1 (18.2)
VAS-global status 68.3 (19.8) 66.6 (18.9) 0.9 (19.7)
VAS-respiratory 70.9 (22.2) 64.1 (21.2) 2.3 (19.9)
Comparison versus baseline.
MLHQ  Minnesota Living With Heart Failure Questionnaire; VAS Visual Analog Scale.F (18%) in the tolvaptan-treated group, compared with 11
*
ceaths (9%) and 34 HF hospitalizations (28%) in the
lacebo-treated group. In a time-to-event analysis, there
as significant favorable effect of tolvaptan on the compos-
te of mortality or HF hospitalization (p  0.03 by log-rank
est) (Fig. 1).
ffects on neurohormonal measurements. Changes in
eurohormones measured in this trial are depicted in Table 7.
asopressin levels increased as expected during receptor
lockade compared with placebo treatment. A histogram of
he magnitude in changes in vasopressin levels in the
olvaptan-treated patients and in the placebo-treated patients
rom baseline to the end of the trial is shown in Figure 2.
rain natriuretic peptide levels decreased during both
olvaptan and placebo therapy (with large standard devia-
ions), decreasing more during tolvaptan therapy, although
he between-group difference was not significant.
ide effects and safety assessments. The most commonly
eported side effects reported during the trial are listed in
able 8. Side effects of urinary frequency, thirst, and dry
outh were more commonly reported during tolvaptan
herapy than during placebo therapy. However, there was
o difference in the number of patients withdrawn from
he trial as the result of bothersome side effects between
he 2 randomization groups. There was no difference
n the incidence of serious adverse events between the 2
roups.
iscussion
he results of the present study demonstrate that 1 year of
herapy with the orally active specific vasopressin V2 recep-
or antagonist tolvaptan did not clearly affect LV remodel-
ng. Vasopressin V2 receptor antagonism with this agent
as well tolerated for the 1 year of treatment, with serious
ide effects generally similar to placebo and no important
hange in laboratory parameters, in this trial representing
Scoring
ek 28  Week 54
cebo p Value* Tolvaptan Placebo p Value*
(17.7) 0.99 4.6 (20.6) 5.6 (17.6) 0.69
(17.6) 0.88 0.6 (22.5) 1.4 (19.4) 0.78
(19.4) 0.17 1.1 (20.2) 6.8 (20.2) 0.18
atients’ Assessment of Overall Treatment Effect
Table 6 Patients’ Assessment of Overall Treatment Effect
 Week 28*  Week 54†
Tolvaptan
n  95
Placebo
n  102
Tolvaptan
n  92
Placebo
n  91
Better 48 41 45 31
About the same 45 53 39 54
Worse 2 7 8 6VAS
 We
Pla
7.2
2.0
3.6Comparison of the change in proportions from baseline to week 28: p 0.09; †comparison of the
hange in proportions from baseline to week 54: p  0.10.
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Effect of Vasopressin Antagonism on Remodeling June 5, 2007:2151–9he longest exposure of HF patients to this therapy. There
as a trend toward a higher percentage of patients in this
ample reporting feeling “better” on the active therapy
ompared with placebo, though with no change in the
alidated Minnesota Living with Heart Failure quality of
ife questionnaire between the groups. In a nonprespeci-
ed analysis, therapy with tolvaptan was associated with
significant reduction in the combined end point of
ortality or HF hospitalization in a time-to-event analysis.
The role of vasopressin in patients with HF has been
tudied as far back as 1968, when Yamane (15), using an
lder assay system, reported that 50% of patients with
dvanced HF had increased vasopressin levels. Using more
odern radioimmunoassay techniques, several studies have
eported that mean levels of plasma vasopressin were greater
n patients with HF or postmyocardial LV dysfunction than
n referent control patients (16,17). However, vasopressin
evels vary widely and are not uniformly increased in patients
ith HF or LV dysfunction (18).
Investigation into antagonizing vasopressin in human HF
egan with the use of an acute V1 receptor antagonist, with
reager et al. (19) finding reductions in systemic vascular
esistance and increases in cardiac output. Since that initial
Figure 1 Effect of TLV on Time to Death or Heart Failure Hospi
Time-to-event analysis evaluating patients randomized to tolvaptan (TLV) (red line)
regard to death or hospitalization for worsening heart failure. There was a favorabl
hanges in Measured Neurohormones
Table 7 Changes in Measured Neurohormones
Baseline (SD)
Tolvaptan Placebo Tolvaptan
Vasopressin (pg/ml) 1.9 (1.7) 2.0 (1.8) 0.5 (1.2)
BNP (pg/ml) 420.1 (469.9) 353.5 (372.0) 89.2 (429.5
Norepinephrine (pg/ml) 648.7 (344.8) 636.5 (287.5) 63.1 (450.6
Plasma renin (ng/ml/h) 17.1 (47.3) 14.8 (21.3) 3.3 (50.6)NP  brain natriuretic peptide.tudy, in the contemporary era there are several nonpeptide
asopressin antagonists that have been investigated in short-
erm studies. A single-dose placebo-controlled study of the
ual V1/V2 receptor antagonist conivaptan in patients with
dvanced HF demonstrated reductions in left- and right
entricular filling pressures and a dose-related increase in
rine output (3). Gheorghiade et al. (5) reported that V2
eceptor antagonism treatment with tolvaptan over the
ourse of 1 month in stable HF patients with signs of
olume overload was associated with reduction in body
eight (as a marker for volume homeostasis) and normal-
zation of serum sodium in a subgroup with hyponatremia.
n the ACTIV in CHF (Acute and Chronic Therapeutic
mpact of a Vasopressin 2 Antagonist [Tolvaptan] in
ongestive Heart Failure) trial of patients with admission
or decompensated HF, treatment with tolvaptan in addi-
ion to standard therapies was associated with an incremen-
al reduction in body weight compared with placebo early in
he hospital course (4). During 60 days of therapy, there was
trend toward favorable effect on the high mortality rate in
his syndrome, and significant reductions in mortality were
oted in very high-risk subgroups, such as those with
yponatremia, increased BUN, or multiple signs of conges-
tion
s placebo (PLC) (blue line) with
ct of TLV on this combined end point.
k 28  (SD) Week 54  (SD)
Placebo p Value Tolvaptan Placebo p Value
0.3 (2.1) 0.03 0.3 (1.1) 0.4 (1.4) 0.01
22.4 (282.8) 0.34 95.3 (385.3) 73.4 (243.2) 0.83
1.3 (314.8) 0.61 88.7 (456.7) 79.1 (415.7) 0.88
2.6 (17.7) 0.57 1.8 (24.8) 1.0 (20.5) 0.91taliza
versu
e effeWee
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June 5, 2007:2151–9 Effect of Vasopressin Antagonism on Remodelingion. Lixivaptan, a highly specific V2 receptor antagonist,
as been shown to have favorable effects on serum sodium in
yponatremic patients with cirrhosis (20) and to result in a
ose-related increase in urine output in patients with HF
nd systolic dysfunction (21).
There is substantial rationale for assessing the effect of a
ovel therapeutic agent HF on the process of remodeling.
herapeutic agents with favorable effects on remodeling,
uch as ACE inhibitors (7,8) or beta-adrenergic blockers
9), generally are associated with favorable effects on natural
istory. Agents with neutral or unfavorable effects on
emodeling relative to a comparator have been found to be
ssociated with neutral or unfavorable effects on natural
istory, such as omapatrilat (12,22) or ibopamine (23,24)
espectively. Such findings have led to the suggestion that
ffects on remodeling may be viewed as a surrogate for
otential effects of a therapy on natural history in HF
atients (25).
In the present study, there was no clear favorable effect of
olvaptan on measures of remodeling, although small direc-
ionally favorable changes were observed that were not
tatistically significant. It is of interest that, in the placebo-
reated group, there was no change in the mean LV volumes
f this HF population sample during 1 year of observation.
n many previous studies, LV volumes in HF patients have
ncreased over time (7,9), representing what is thought to be
he progressive remodeling process in HF. The population
ample in this study was very well treated in terms of
ackground evidence-based therapies, with 90% use of
Figure 2 Effect of Tolvaptan and Placebo on VP Levels During t
Histogram of changes in vasopressin (VP) levels from baseline to week 54 (in pg/
bars). Group changes were significant (Table 7). The histogram of the changes in
increase in the patients randomized to tolvaptan, as shown in Table 7.CE inhibitors or angiotensin receptor blockers, and ap- Aroximately 90% use of beta-adrenergic blockers. It is
onceivable that, with such high use of background thera-
ies, the temporal pace of the process of remodeling has
hanged compared with previous studies and that, in this
etting, longer observation periods and/or larger sample
izes may be required to demonstrate remodeling effects of
new therapy.
It has been suggested that chronic treatment with specific
asopressin V2 receptor antagonists (with subsequent eleva-
ion of vasopressin serum levels) may actually have an
ourse of the Trial
patients randomized to tolvaptan (open bars) or to placebo (cross-hatched
ual patients shows a shift to the right, which is consistent with the significant
ost Frequent Side Effects and Safety Assessments
Table 8 Most Frequent Side Effects and Safety Assessments
Tolvaptan
(n  120)
n (%)
Placebo
(n  120)
n (%) p Value
Subjects with AEs 116 96.7 112 93.3 0.38
Urinary frequency 38 31.7 6 5.0 0.01
Thirst 32 26.7 7 5.8 0.01
HF aggravated 22 18.3 34 43.4 0.09
Dry mouth 16 13.3 2 1.7 0.01
Dizziness 16 13.3 16 13.4 1.00
Subjects with serious AEs 48 40.0 52 43.3 0.69
HF aggravated 16 13.3 22 18.4 0.38
Pneumonia 6 5.0 3 2.5 0.50
Ventricular tachycardia 4 3.3 1 0.8 0.37
Chest pain 4 3.3 5 4.2 1.00
Dehydration 3 2.5 1 0.8 0.62
Subjects discontinued because
of AEs
14 11.7 15 12.5 1.00
Deaths 6 5.0 11 9.2 0.31he C
ml) for
individE  adverse event; HF  heart failure.
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Effect of Vasopressin Antagonism on Remodeling June 5, 2007:2151–9dverse effect on the process of LV remodeling, based on
hronic stimulation of vasopressin V1A receptors (26). The
1A receptor is found on vascular smooth muscle cells as
ell as myocytes (1,27). Stimulation of the V1A receptor
esults in vasoconstriction in the peripheral and coronary
irculations and has other effects, including increasing
ntracellular calcium levels in cardiac myocytes (1,28,29).
tudies also have demonstrated that vasopressin increases
he rate of protein synthesis in the myocardium, leading to
yocyte hypertrophy, a direct effect mediated by the V1A
eceptor (29–32). All of these effects might theoretically be
xpected to have a potential adverse influence on remodel-
ng. Indeed, in this trial, vasopressin levels across the course
f the trial were greater (measured at week 28 and at week
4) during vasopressin V2 blockade with tolvaptan than in
lacebo treated patients (Table 7, Fig. 2). However, the data
rom this study, demonstrating no significant change in LV
olumes with 1 year of tolvaptan therapy, rules out with
easonable certainty an adverse effect of unopposed V1A
eceptor stimulation during chronic specific vasopressin V2
eceptor antagonism.
An intriguing and potentially clinically relevant finding
rom the present study was the reduction in the composite
utcome of mortality and HF hospitalization over 1 year of
olvaptan therapy. The strength of this finding is con-
trained by several factors. This was not a prespecified end
oint, and the outcome events were not adjudicated by a
linded central events committee. Rather, the events were
nvestigator-reported, although the investigators were
linded as to whether the patients were on active therapy or
lacebo. The mortality findings in this study over 1 year of
herapy are similar to those observed in the ACTIV in CHF
rial of 60 days of therapy with tolvaptan in patients with
cute decompensated HF (4). These outcome findings must
e considered hypothesis generating and are being tested
rospectively in the well-powered EVEREST (Endovascu-
ar Valve Edge-to-Edge Repair Study) trial (11), which
xamines short- and long-term effects of tolvaptan on early
ymptomatic improvement and long-term natural history in
F patients after an acute decompensation. A recent study
as reported that clinically occult volume overload in HF
atients is associated with unfavorable natural history com-
ared with euvolemic patients (33), suggesting that control
f volume status over long-tern therapy may be associated
ith reduced outcome risk.
The safety data from this trial reflect the longest exposure
f HF patients to date to vasopressin receptor antagonism.
s in previous studies (4), there was an excess of thirst as a
ide effect in the tolvaptan-treated group. However, the
ncidence of withdrawal from the study was similar between
he treated and the placebo groups, as were the incidences of
dverse effects and serious adverse effects. Also similar to
revious studies, there was no adverse change in renal
unction or electrolytes during tolvaptan therapy (4). The
verall data suggest that vasopressin V2 receptor antag-nism over this period of time is relatively safe and well
olerated.
Hence, in a well-treated population of stable HF patients,
V volumes were stable during the course of 1 year of
ollow-up. There was no significant effect of tolvaptan
herapy on LV volumes or function observed during 1 year
f therapy. There was no adverse effect on remodeling
bserved, suggesting that a chronic V1A receptor effect
uring V2 receptor antagonism is not clinically important.
onprespecified natural history data favored therapy with
olvaptan, with a statistically significant reduction in mor-
ality and HF hospitalization observed. Tolvaptan therapy
or 1 year was as safe and as well tolerated as placebo. An
ngoing phase 3 study (EVEREST) will test with sufficient
ower and prospective design the observed favorable effects
n outcomes and the nonsignificant directional trends in
emodeling and symptom parameters observed in this trial.
eprint requests and correspondence: Dr. James E. Udelson,
ufts-New England Medical Center, 750 Washington Street, Box
0, Boston, Massachusetts 02111. E-mail: JUdelson@tufts-
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lease see the online version of this article.
